ACP
TNGX icon

Acuta Capital Partners’s Tango Therapeutics TNGX Stock Holding History

Acuta Capital Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Sell
390,949
-50,882
-12% -$1.26M 8.52% 3
2026
Q1 		$9.24M Buy
441,831
+159,099
+56% +$2.21M 6.52% 4
2025
Q4 		$2.51M Buy
+282,732
New +$2.44M 1.7% 14

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Acuta Capital Partners's TNGX Position: Q2 2026 in Review

Acuta Capital Partners reduced its Tango Therapeutics (TNGX) stake by 12% in Q2 2026, selling an estimated $1.26M and leaving 390,949 shares worth $12.2M. The position accounts for 8.52% of the portfolio, ranked #3.

Acuta Capital Partners first reported a position in TNGX in Q4 2025 and has held it in 3 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Acuta Capital Partners held 390,949 shares of Tango Therapeutics worth $12.2M as of Q2 2026.
  • Acuta Capital Partners sold 50,882 Tango Therapeutics shares in Q2 2026, an estimated $1.26M.
  • Tango Therapeutics made up 8.52% of Acuta Capital Partners's portfolio in Q2 2026, its #3 holding.
  • Acuta Capital Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.